US EditionEurope Leads Pioneering Research with Oncolytic Viruses Against Advanced Ovarian Cancer
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
With more than 3,500 new cases a year in Spain, ovarian cancer is the eighth most frequent in women, one of the most aggressive and usually diagnosed in advanced stages. Now, an international clinical trial is going to study in women with advanced ovarian cancer an innovative therapeutic strategy based on on oncolytic viruses, a treatment capable of selectively attacking tumor cells and activating the immune system response. The study, in phase …
An international clinical trial will study in women with advanced ovarian cancer an innovative therapeutic strategy based on on oncolytic viruses, a treatment capable of selectively attacking tumor cells and activating the response of the immune system. The study, in phase II and funded by the Horizon Europe program of the European Union, has opened at the Cancer Center Clínica Universidad de Navarra (CCUN) and at the Catalan Institute of Oncolo…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
